Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.

Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.

<h4>Background</h4>Ideally, disease modifying therapies for Alzheimer disease (AD) will be applied during the 'preclinical' stage (pathology present with cognition intact) before severe neuronal damage occurs, or upon recognizing very mild cognitive impairment. Developing and j...

Full description

Bibliographic Details
Main Authors: Richard J Perrin, Rebecca Craig-Schapiro, James P Malone, Aarti R Shah, Petra Gilmore, Alan E Davis, Catherine M Roe, Elaine R Peskind, Ge Li, Douglas R Galasko, Christopher M Clark, Joseph F Quinn, Jeffrey A Kaye, John C Morris, David M Holtzman, R Reid Townsend, Anne M Fagan
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21264269/pdf/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21264269/pdf/?tool=EBI

Similar Items